anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients in this arm are discharged from the Northwestern Emergency Department with standard communication about their prescribed opioid pain medication from their care providers. They are called for a follow up survey 4-7 days after their visit.
Patients receive talimogene laherparepvec IT or via intralesional injection at weeks 1, 4, 6 and 8. Beginning 1 week after the start of talimogene laherparepvec, patients undergo radiation therapy on Monday-Friday of weeks 2-6. Patients undergo collection of blood and a tumor biopsy on study and undergo MRI throughout the trial.
### Teratogenic Effects

Category C. Terfenadine alone was not teratogenic in rats and rabbits at oral doses up to 300 mg/kg; 300 mg/kg of terfenadine produced fexofenadine AUC values that were approximately 4 and 30 times, respectively, the AUC at the maximum recommended human daily oral dose of ALLEGRA-D 12 HOUR.

In mice, no adverse effects and no teratogenic effects during gestation were observed with fexofenadine at dietary doses up to 3730 mg/kg (approximately 15 times the maximum recommended human daily oral dose of ALLEGRA-D 12 HOUR based on comparison of the AUCs).

The combination of terfenadine and pseudoephedrine hydrochloride in a ratio of 1:2 by weight was studied in rats and rabbits. In rats, an oral combination dose of 150/300 mg/kg produced reduced fetal weight and delayed ossification with a finding of wavy ribs. The dose of 150 mg/kg of terfenadine in rats produced an AUC value of fexofenadine that was approximately 4 times the AUC at the maximum recommended human daily oral dose of ALLEGRA-D 12 HOUR. The dose of 300 mg/kg of pseudoephedrine hydrochloride in rats was approximately 10 times the maximum recommended human daily oral dose of ALLEGRA-D 12 HOUR on a mg/m2 basis. In rabbits, an oral combination dose of 100/200 mg/kg produced decreased fetal weight. By extrapolation, the AUC of fexofenadine for 100 mg/kg orally of terfenadine was approximately 10 times the AUC at the maximum recommended human daily oral dose of ALLEGRA-D 12 HOUR. The dose of 200 mg/kg of pseudoephedrine hydrochloride was approximately 15 times the maximum recommended human daily oral dose of ALLEGRA-D 12 HOUR on a mg/m2 basis.

There are no adequate and well-controlled studies in pregnant women. ALLEGRA-D 12 HOUR should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

### Nonteratogenic Effects

Dose-related decreases in pup weight gain and survival were observed in rats exposed to an oral dose of 150 mg/kg of terfenadine; this dose produced an AUC of fexofenadine that was approximately 4 times the AUC at the maximum recommended human daily oral dose of ALLEGRA-D 12 HOUR.
All patients have been treated by INVAC-1 vaccine during the previous phase 1 NCT02301754. No new treatment injection is required in this study.
The invention discloses mulberry leaf lipid-reducing pressure-reducing health-care tea and a preparation method thereof. The mulberry leaf health-care tea comprises mulberry leaf main materials and traditional Chinese medicine auxiliary materials, wherein the traditional Chinese medicine auxiliary materials comprise eucommia ulmoides, angelica sinensis, poria cocos, viola philippica, codonopsis pilosula, polygala tenuifolia, gynostemma pentaphyllum, ligusticum wallichii, polygonatum odoratum, peach kernel, curcuma aromatic, raw rehmannia, radix angelicae dahuricae, earthworm, salviae miltiorrhizae, dandelion, glossy privet fruit, oldenlandia diffusa and white peony root. The invention overcomes the defects of the mulberry leaf tea is easy to yellow by heaping and fragile and the soup color is red. The advanced process of teat processing is integrated into manufacturing of the mulberry tea, the traditional tea-making deactivating technology is applied to development of the mulberry leaf, and the systematic research on the mulberry leaf tea preparation is performed by synthesizing various technological factors, so the developed mulberry leaf tea has good mouthfeel, high fragrance and no green smell and can be accepted by customers. The research proves that the mulberry leaf juice has anti-oxidant effect, no toxicity and no chemical pollution, and is expected to be an additive for food and health-care products. The traditional Chinese medicinal materials which can promote blood circulation, remove blood stasis, reduce blood sugar and reduce blood lipid are adopted and most of the traditional Chinese medicinal materials have light mouthfeel, so the taste of the mulberry leaf tea is not influenced, the mulberry leaf is easily accepted by people suffering from hypertension, hyperlipidemia and hyperglycemia, and the health-care effect can be achieved better.
Three MRIs will be performed. One at baseline, one within 72 hours postoperative, and one 2-3 weeks postoperative.
The ZF2001 vaccine has demonstrated high efficacy in preventing coronavirus disease 2019 (COVID-19). However, the clinical characteristics of breakthrough infections in vaccinated individuals and the risk factors for adverse outcomes in COVID-19 patients remain unclear. We conducted a retrospective single-center cohort study at Xiangya Hospital of Central South University, including 210 fully vaccinated COVID-19 inpatients from December 5, 2022, to January 31, 2023. Data on clinical characteristics, laboratory findings, disease severity, treatment, and prognosis were collected and analyzed. Our findings revealed that COVID-19 inpatients still experienced common symptoms at the onset of illness, but most laboratory findings were within the normal range, except for white blood cell count (WBC), lymphocyte count, and lactate dehydrogenase (LDH) levels. Following standard treatment, 95.7% of patients were discharged from the hospital. We identified seven variables significantly associated with a higher risk of adverse outcomes, including age over 65, elevated WBC count, reduced lymphocyte count, higher levels of blood urea nitrogen (BUN), LDH, troponin, D-dimer, and procalcitonin. This study supports the substantial clinical benefits of the ZF2001 vaccine for COVID-19 patients. Additionally, age over 65, elevated WBC count, reduced lymphocyte count, and higher blood levels of BUN, LDH, D-dimer, and procalcitonin may be used as predictive factors for disease progression in fully vaccinated COVID-19 inpatients.
UNLABELLED: Growing evidence indicates a relationship between telomere length (TL) and the stage, prognosis, and treatment responsiveness of hematopoietic malignancies. However, the relationship between TL and the risk of hematologic malignancies remains unclear, considering the vulnerability of observational studies to potential confounding and reverse causation. A two-sample bidirectional Mendelian randomization (MR) analysis was conducted utilizing publicly available genome-wide association study data to assess whether TL was causally associated with the risk of hematologic malignancies. The inverse variance weighted approach was used as the primary assessment approach to evaluate the effects of the causes, augmented by the weighted median and MR-Egger methods. Cochran's Q test, MR-Egger intercept test, MR-Pleiotropy Residual Sum and Outlier test, and leave-one-out analysis were performed to evaluate sensitivity, heterogeneity, and pleiotropy. According to forward MR estimations, longer TL was related to an increased risk of acute lymphocytic leukemia (OR = 2.690; P = 0.041), chronic lymphocytic leukemia (OR = 2.155; P = 0.005), multiple myeloma (OR = 1.845; P = 0.024), Hodgkin lymphoma (OR = 1.697; P = 0.014), and non-Hodgkin lymphoma (OR = 1.737; P = 0.009). Specific types of non-Hodgkin lymphoma were also associated with TL. The reverse MR results revealed that hematologic malignancies had no effect on TL. This MR analysis revealed an association between longer TL and an increased risk of specific hematologic malignancies, indicating a potential role of TL in risk evaluation and management in hematologic malignancies.
SIGNIFICANCE: In contrast to observational studies, this study uncovered the reliable causal relationships between TL and hematologic malignancies, emphasizing the potential role of telomeres in tumor development. TL maintenance may offer a promising strategy to reduce the risk of hematologic malignancies.
<P>PROBLEM TO BE SOLVED: To provide an eye-wiping water that is prepared by fluidizing plant components good for eyes, decomposes eye mucus or the like and gives the eyes vitality thereby preventing the impediment of eyes and improving visual acuity.  <P>SOLUTION: This invention is that (1) medicinal herbs and vegetables are eluted with Japanese Sake for more than 3 weeks to collect the eluent and further (2) the eluent is allowed to elute medicinal herbs and vegetable and the resultant eluate is used as an eye-wiping water. As it can remove even the solid contaminants causing glaucoma, the eluate can prevent glaucoma. By wiping eyes with the eluate, the solid contaminants are decomposed to effect the disinfection and pasteurization and increase vitality. Thus, vivid and healthy eyes are restored and the visual acuity is improved by the excellent effect of the eluate.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
PURPOSE: An antibacterial extract isolated from persimmon leaf is provided to ensure antibacterial activity to helicobacter pylori and to prevent and treat gastric cancer and gastritis. CONSTITUTION: A persimmon leaf extract is isolated using alcohol, ethyl acetate, chloroform, methyl ethyl ketone, acetone, methylene chloride, or ether. The persimmon leaf extract is additionally purified using hexane:chloroform:ethanol through chromatography. The mixture ratio of hexane, chloroform, and ethanol is 3-7:0.5-1.5:0.5-1.5. A pharmaceutical composition for preventing and treating intestinal disease contains the persimmon leaf extract. The intestinal disease is gastric ulcer, gastric cancer, and gastritis.
PURPOSE: A method for preparing lipophilic VItis vinifera extract is provided to use as excipient of a cosmetic composition containing lipid phase. CONSTITUTION: A lipophilic Vitis vinifera extract is obtained by extracting lignum of the Vitis vinifera such as buds, stem and roots with non polar solvent. The Vitis vinifera is species such as Merlot, Cabernet Franc, Gamay, Syrah, Semillon or Sauvignon. The non polar solvent is cyclohexane, C6 or C7 alkan such as n-hexane or heptanes, supercritical or subcritical. The extraction temperature is 15°C to 18°C. A cosmetic composition contains lipophilic Vitis vinifera extract. The composition contains one or more fatty phase. The composition is used for care of skin, lip, or integument, or make-up. The composition is used in the form of lipstick or mascara.
PURPOSE:To prepare a self-adhesive poultice having excellent water-retainability and shape-retainability, by dissolving gelatin and a polyacrylic acid in water, adjusting the pH of the solution to a specific level, adding a dialdehyde starch uniformly to the solution, and adjusting the pH of the solution to a specific level with a hardly soluble weak acid metal salt. CONSTITUTION:A mixture of 1pts.wt. of gelatin with 1-5pts.wt. of a polyacrylic acid or polyacrylic acid-alkali metal polyacrylate mixture is dissolved in water, adjusted to 2.5-5.5pH, added with 0.01-0.5pt.wt. of dialdehyde starch, and mixed homogeneously. A desired components such as active drug components, etc. are added to the mixture in an arbitrary step in the above process. The pH of the mixture is raised to 5.5-7 by adding a hardly soluble metal salt of a monobasic acid or a polybasic acid having a pKa of >=4 (e.g. barium carbonate) or a hardly soluble metal oxide (e.g. zinc oxide), and the crosslinking gelation reaction is slowly proceeded to obtain a uniform crosslinked gel. Since the reaction proceeds under mild condition, the complicated and strict operation control becomes unnecessary.
The study is recruiting people with cystic fibrosis (CF). The medical record is being extracted, and a blood sample is taken for DNA. The DNA samples are tested for variation both at the cystic fibrosis transmembrane conductance regulator (CFTR) gene (the CF gene) and over the entire rest of the genome. Using large numbers of people with CF, and knowing who does and does not have CFRD, we identify genetic variations that associate with CFRD. Knowing these variations allows us to better understand the causes of CFRD, and with enough information, better to predict CFRD and identify people at particularly high or low risk of CFRD. People participating in this study also have the option to participate in related studies of other metabolic traits in CF such as over- and underweight.
Health Educators (HEs) will meet briefly with eligible participants after each office visit to review a prediabetes decision aid. Additionally, participants will receive biweekly messages throughout the 12-month trial. Automated messages will be sent using an existing secure text messaging platform.
There is provided an apparatus for performing operation steps of a dialysis process. The apparatus comprises a process controller for controlling the apparatus, monitor process progress of the dialysis process and monitor sensor inputs from sensors of the apparatus, and a user interface, UI, comprising a display, an input device and a UI controller. The UI controller is connected to enable presentation of graphical data on the display. The UI controller is connected to enable user interaction with the graphical data and connected to exchange information with the process controller. The UI controller is configured to represent each of the operation steps by step items. The amount of operation guidance information of an operation step item is selectable by the operator during the dialysis process. A method and computer program are also disclosed.
FIELD: organic chemistry. SUBSTANCE: method involves interaction of 8,9-dihydroelimoclavine with 1-iodopropane, sulfonyl halide and alkaline metal thiomethoxide without isolation of intermediate compounds. Solvents - N-methylpyrrolidone and pyridine are used by this method. Method can be used in pharmacy of the known drug pergolide used for treatment of patients with Parkinson's disease. EFFECT: improved method of synthesis. 2 cl
PROBLEM TO BE SOLVED: To provide a human fibroblast growth factor-13 polypeptide and a DNA (an RNA) capable of encoding the polypeptide. SOLUTION: A process for preparing the polypeptide by a recombinant technique is provided. A process for utilizing the polypeptide for promoting wound healing, e.g. as a result of burns and ulcers to prevent neuronal damage associated with stroke and due to neuronal disorders and promote neuronal growth, to prevent skin aging and hair loss and to stimulate angiogenesis and mesodermal induction in early embryos and limb regeneration. Furthermore, an antagonist against the polypeptide and the use thereof as a therapeutic method for preventing abnormal cellular proliferation, hyper-vascular diseases and epithelial lens cell proliferation are disclosed. A diagnostic method for detecting mutations in a coding sequence and an alteration in the concentration of the polypeptide in a sample obtained from a host is also disclosed.
An antibiotic composition particularly for veterinary use comprises 10-100 mg. per mil of tetracycline, oxytetracycline or chlorotetracycline in a mineral oil containing a non-toxic polyvalent metallic salt of a fatty acid.  It is preferred to use 0.5 to 5 per cent (based on the composition) of the metallic salt. The gas produced by heating the mineral oil with the metallic salt and then cooling, is mixed cold with the antibiotic, which may be the free base or any therapeutically active form such as the hydrochloride. The addition of 1/10th volume of water, based on the mineral oil content, increases the initial absorption of the antibiotic on injection.  Specified metallic salts and aluminium stearate, calcium stearate, magnesium stearate, calcium oleate, aluminium oleate and calcium myristate.  Specification 714,085 is referred to.
* Pyridostigmine bromide is approved as a pretreatment for protection against the chemical nerve agent soman (GD). PB has not been approved for use against other chemical nerve agents including Sarin (GB), Tabun (GA), and VX. [See Indications and Usage (1).]   
The approval is based on safety studies in humans and effectiveness studies conducted in animals. The FDA has approved pyridostigmine bromide based only on animal studies of effectiveness because it is not ethical to do these studies in humans. Human studies would require exposing people to the deadly effects of nerve agents, risking poisoning them or even killing them. Studies in monkeys and guinea pigs show that pretreatment with pyridostigmine bromide makes the antidotes (atropine and 2-PAM) work better against soman (GD). [See Nonclinical Toxicology (13.2).]
  * The main protection against chemical weapons is the chemical protective mask and battle dress overgarments. [See boxed WARNINGS and Dosage and Administration (2).]
  * Pyridostigmine bromide is used as a pretreatment against a soman nerve agent attack. Based on the animal studies, it is thought that any potential benefits from use of pyridostigmine bromide occur only if:

(1)
     It is taken within 8 hours before, but not right before, exposure to the nerve agent soman. If it is taken right before (when the nerve gas attack alarm is given) or during nerve agent exposure, it may not work and may make the effects of soman worse.
(2)
     Atropine and 2-PAM are used when symptoms of nerve agent poisoning occur. The two antidotes are part of the ATNAA (Antidote Treatment – Nerve Agent Autoinjector). See Dosage and Administration (2).
In this arm, we will apply for NIOD first which will be performed by non-physiotherapists such as respiratory therapists and bedside nurses. This arm of patients will receive standard CPT at least 3 hours after the NIOD intervention.
Glioblastomas (GBMs) are characterized by high heterogeneity, involving diverse cell types, including those with stem-like features contributing to GBM's malignancy. Moreover, metabolic alterations promote growth and therapeutic resistance of GBM. Depending on the metabolic state, antimetabolic treatments could be an effective strategy. Against this background, we investigated temporal and regional expression changes and co-staining patterns of selected metabolic markers [pyruvate kinase muscle isozyme 1/2 (PKM1/2), glucose transporter 1 (GLUT1), monocarboxylate transporter 1/4 (MCT1/4)] in a rodent model and patient-derived samples of GBM. To understand the cellular sources of marker expression, we also examined the connection of metabolic markers to markers related to stemness [Nestin, Krüppel-like factor 4 (KLF4)] in a regional and temporal context. Rat tumour biopsies revealed a temporally increasing expression of GLUT1, higher expression of MCT1/4, Nestin and KLF4, and lower expression of PKM1 compared to the contralateral hemisphere. Patient-derived tumours showed a higher expression of PKM2 and Nestin in the tumour centre vs. edge. Whereas rare co-staining of GLUT1/Nestin was found in tumour biopsies, PKM1/2 and MCT1/4 showed a more distinct co-staining with Nestin in rats and humans. KLF4 was mainly co-stained with GLUT1, MCT1 and PKM1/2 in rat and human tumours. All metabolic markers yielded individual co-staining patterns among themselves. Co-staining mainly occurred later in tumour progression and was more pronounced in tumour centres. Also, positive correlations were found amongst markers that showed co-staining. Our results highlight a link between metabolic alterations and stemness in GBM progression, with complex distinctions depending on studied markers, time points and regions.
The mpMRIs were performed on a 1.5T GE MR unit or on a 3T GE or Philips MR units. All mpMRIs included T2-weighted imaging, diffusion-weighted imaging (maximal b value: 2000 s/mm²) and dynamic contrast-enhanced imaging.
Milnacipran helps serotonin and noradrenaline work more effectively on the central nervous system. Serotonin and noradrenaline are molecules made by the brain that affect how your body responds to pain. Milnacipran, a dual norepinephrine and serotonin reuptake inhibitor has been a safe and beneficial treatment for patients with fibromyalgia and may be useful to treat patients with painful peripheral neuropathy. Many clinical trials for neuropathy pain are done in patients with diabetic neuropathy. Idiopathic neuropathy however, is a common cause of neuropathy and accounts for 25% of all neuropathies, and over 50% of small fiber neuropathies. The information in this study will provide information on whether milnacipran also provide benefit as a medication for neuropathic pain.
PURPOSE:To obtain a plasma-originated protein having little odor and low content of coloring substance with simple procedure by treating plasma with an acidic or basic substance and removing the denaturated hemoglobin. CONSTITUTION:To remove a discoloration-causing substance from plasma, the plasma is treated with an acidic or basic substance and the denaturated hemoglobin is removed. Concretely, an acidic substance (preferably hydrochloric acid, phosphoric acid, acetic acid, etc.) is added to the plasma to adjust the pH to 3-6 or a basic substance (preferably sodium hydroxide or potassium hydroxide) is added to the plasma to adjust the pH to 9-13, the mixture is maintained at 0-40 deg.C to effect the denaturation of hemoglobin and the denaturated hemoglobin is removed from the system. A representative method for further improving the purification effect of plasma is the treatment of plasma with polymer electrolyte and then activated carbon and, finally, the pH-modification treatment. In addition to the above procedures, the plasma is filtered with a ceramic filter.
This study aims at investigating anthropometric, body composition and performance indicators among male youth soccer players. The study will be conducted prior to the preparation period. Initially, participants and their parents (for those under 18 years) will be informed about the benefits, risks and discomforts associated with the study and will provide a written consent. Participants will be instructed to refrain from strenuous exercise for at least 48 hours prior to testing and they will be also asked to consume their normal diet. Prior to testing all participants will be familiarized with testing procedures and specific test. Body weight will be measured on a seca beam balance. Participants' height will be measured by using a fixed stadiometer and the percent body fat will be calculated with bioelectrical impedance analysis. Flexibility will be assessed by using the sit and reach test and the lower body explosive strength will be determined through vertical jump testing (squat jump and counter movement jump without arm swing). Knee flexor and extensor strength will be assessed on an isokinetic dynamometer. Sprint performance will be assessed from a standing start over by infrared photocells with participants running 10m and 30m as fast as they can. The repeated sprint ability will be tested by using linear sprint test including 5 maximum sprints of 30 meters with a 25-second recovery period in-between. Maximal oxygen consumption (VO2max) will be determined by open-circuit spirometry via breath-by-breath analysis during a graded exercise test to exhaustion on a treadmill. Furthermore, participants will be evaluated in agility by using the short dribbling test and the ability to recover after repeated intense exercise through the YO-YO Intermittent Recovery test 1 (only for u-16 and U-18 groups).